The biotech reported good results for a late-stage trial of its drug Abraxane in melanoma patients. The company said the study met its primary endpoint in that patients demonstrated a statistically significant improvement in survival vs. standard melanoma treatment. Celgene (CELG) said a full report will be issued at a melanoma conference in November. Celgene shares rose 2.1% to 78.42.
- Pharmaceuticals & Drug Trials